Chrdl-1 antigen binding proteins and methods of treatment
OwnerKevin Christopher CORBIT, Christopher J.R. Pasztyinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods relating to or derived from antigen binding proteins to CHRDL-1. Human, humanized, and chimeric antibodies, as well as fragments and derivatives thereof are further contemplated. Other embodiments include nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, as well as polypeptides, cells, methods of making and using antigen binding proteins, fragments and derivatives thereof.
Claims69
A method of treating diabetes in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of treating a diabetes-related condition or disorder in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of treating obesity in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of modulating blood glucose in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of inducing and/or preserving brown fat formation and/or activity in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of treating insulin resistance in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of treating inflammatory disease in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of treating dyslipidemia in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
A method of treating a disease or disorder characterized by undesired levels of triglycerides in a patient comprising administering to said patient an effective amount of an antigen binding protein capable of inhibiting an activity of CHRDL-1.
An isolated antigen binding protein comprising SEQ ID NO:
- 8, SEQ ID NO:
- 9, and SEQ ID NO:
- 10.
An isolated antigen binding protein comprising SEQ ID NO:
- 20, SEQ ID NO:
- 21, and SEQ ID NO:
- 22.
An isolated antigen binding protein comprising SEQ ID NO:
- 26, SEQ ID NO:
- 27 and SEQ ID NO:
- 28.
An isolated antigen binding protein comprising SEQ ID NO:
- 37, SEQ ID NO:
- 38 and SEQ ID NO:
- 39.
An isolated antigen binding protein comprising SEQ ID NO:
- 40, SEQ ID NO:
- 41 and SEQ ID NO:
- 42.
An antibody comprising SEQ ID NO:
- 49.
An antibody comprising SEQ ID NO:
- 50.
An antibody comprising SEQ ID NO:
- 55.
An antibody comprising SEQ ID NO:
- 56.
An antibody comprising SEQ ID NO:
- 57.
An antibody comprising SEQ ID NO:
- 58.
An antibody comprising SEQ ID NO:
- 59.
An antibody comprising SEQ ID NO:
- 60.
An antibody comprising SEQ ID NO:
- 61.
An antibody comprising SEQ ID NO:
- 62.
An antibody comprising SEQ ID NO:
- 65.
An antibody comprising SEQ ID NO:
- 66.
An antibody comprising SEQ ID NO:
- 69.
An antibody comprising SEQ ID NO:
- 70.
An antibody comprising SEQ ID NO:
- 71.
An antibody comprising SEQ ID NO:
- 72.
A nucleic acid comprising any of SEQ ID NOS:
- 5, 6, 7, 11, 12, 13, 17, 18, 19, 23, 24, 25, 30, 32, 34, 36, 44, 46, 73, 74, 75, 76, 77, and 78.
An isolated antigen binding protein having at least 85% sequence identity with any of SEQ ID NO:
- 8, 9, 10, 20, 21, 22, 26, 37, 38, 39, 40, 41, and 42.
An isolated antigen binding protein having at least 90% sequence identity with any of SEQ ID NO:
- 8, 9, 10, 20, 21, 22, 26, 37, 38, 39, 40, 41, and 42.
An isolated antigen binding protein having at least 95% sequence identity with any of SEQ ID NO:
- 8, 9, 10, 20, 21, 22, 26, 37, 38, 39, 40, 41, and 42.
An isolated antigen binding protein comprising a variable region light chain having at least 85% sequence identity with any of light chain SEQ ID NOs:
- 29, 43, 47, 48, 63, and 64.
An isolated antigen binding protein comprising a variable region light chain having at least 90% sequence identity with any of light chain SEQ ID NOs:
- 29, 43, 47, 48, 63, and 64.
An isolated antigen binding protein comprising a variable region light chain having at least 95% sequence identity with any of light chain SEQ ID NOs:
- 29, 43, 47, 48, 63, and 64.
An isolated antigen binding protein comprising a variable region heavy chain having at least 85% sequence identity with any of light chain SEQ ID NOs:
- 31, 35, 45, 51, 52, 53, 54, 67, and 68.
An isolated antigen binding protein comprising a variable region heavy chain having at least 90% sequence identity with any of light chain SEQ ID NOs:
- 31, 35, 45, 51, 52, 53, 54, 67, and 68.
An isolated antigen binding protein comprising a variable region heavy chain having at least 95% sequence identity with any of light chain SEQ ID NOs:
- 31, 35, 45, 51, 52, 53, 54, 67, and 68.
An isolated antigen binding protein comprising a variable region light chain having at least 85% sequence identity with any of light chain SEQ ID NOs:
- 85, 93, 101, 109, 117, 125, 133, 141, and 149.
An isolated antigen binding protein comprising a variable region light chain having at least 90% sequence identity with any of light chain SEQ ID NOs:
- 85, 93, 101, 109, 117, 125, 133, 141, and 149.
An isolated antigen binding protein comprising a variable region light chain having at least 95% sequence identity with any of light chain SEQ ID NOs:
- 85, 93, 101, 109, 117, 125, 133, 141, and 149.
An isolated antigen binding protein comprising a variable region heavy chain having at least 85% sequence identity with any of light chain SEQ ID NOs:
- 86, 94, 102, 110, 118, 126, 134, 142, and 150.
An isolated antigen binding protein comprising a variable region heavy chain having at least 90% sequence identity with any of light chain SEQ ID NOs:
- 86, 94, 102, 110, 118, 126, 134, 142, and 150.
An isolated antigen binding protein comprising a variable region heavy chain having at least 95% sequence identity with any of light chain SEQ ID NOs:
- 86, 94, 102, 110, 118, 126, 134, 142, and 150.
An isolated antigen binding protein comprising at least one of:
- (a) SEQ ID NO:
- 79, SEQ ID NO:
- 80 and SEQ ID NO:
- 81;
- (b) SEQ ID NO:
- 82, SEQ ID NO:
- 83 and SEQ ID NO:
- 84;
- (c) SEQ ID NO:
- 87, SEQ ID NO:
- 88 and SEQ ID NO:
- 89;
- (d) SEQ ID NO:
- 90, SEQ ID NO:
- 91 and SEQ ID NO:
- 92;
- (e) SEQ ID NO:
- 95, SEQ ID NO:
- 96 and SEQ ID NO:
- 97;
- (f) SEQ ID NO:
- 98, SEQ ID NO:
- 99 and SEQ ID NO:
- 100;
- (g) SEQ ID NO:
- 103, SEQ ID NO:
- 104 and SEQ ID NO:
- 105;
- (h) SEQ ID NO:
- 106, SEQ ID NO:
- 107 and SEQ ID NO:
- 108;
- (i) SEQ ID NO:
- 111, SEQ ID NO:
- 112, and SEQ ID NO:
- 113;
- (j) SEQ ID NO:
- 114, SEQ ID NO:
- 115, and SEQ ID NO:
- 116;
- (k) SEQ ID NO:
- 119, SEQ ID NO:
- 120 and SEQ ID NO:
- 121;
- (l) SEQ ID NO:
- 122, SEQ ID NO:
- 123, and SEQ ID NO:
- 124;
- (m) SEQ ID NO:
- 127, SEQ ID NO:
- 128 and SEQ ID NO:
- 129;
- (n) SEQ ID NO:
- 130, SEQ ID NO:
- 131 and SEQ ID NO:
- 132;
- (o) SEQ ID NO:
- 135, SEQ ID NO:
- 136 and SEQ ID NO:
- 137;
- (p) SEQ ID NO:
- 138, SEQ ID NO:
- 139 and SEQ ID NO:
- 140;
- (q) SEQ ID NO:
- 143, SEQ ID NO:
- 144 and SEQ ID NO:
- 145;
- and
- (r) SEQ ID NO:
- 146, SEQ ID NO:
- 147 and SEQ ID NO:
- 148.
A method of converting white adipose tissue to brown adipose tissue comprising administering to a patient an effective amount of a selective binding agent to CHRDL-1.
A method of promoting brown adipose tissue production comprising administering to a patient an effective amount of a selective binding agent to CHRDL-1.
A method of preventing conversion of brown adipose tissue to white adipose tissue comprising administering to a patient an effective amount of a selective binding agent to CHRDL-1.
Dependencies are inferred from the claim text.